• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Prediction of anticancer effect of 1-p-D-arabinofuranosylcytostee by sensitive monitoring of its intracellular active metabolite in leukemic cells

Research Project

Project/Area Number 10670938
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Hematology
Research InstitutionFukui Medical University

Principal Investigator

UEDA Takanori  Fukui Medical University Department of Medicine Professor, 医学部, 教授 (40160171)

Co-Investigator(Kenkyū-buntansha) YAMAUCHI Takahiro  Fukui Medical University University Hospital Assistant Professor, 医学部・附属病院, 助手 (90291377)
Project Period (FY) 1998 – 2001
Project Status Completed (Fiscal Year 2001)
Budget Amount *help
¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2001: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 2000: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1999: ¥500,000 (Direct Cost: ¥500,000)
Keywordsara-C / BHAC / acute leukemia / tailor- made therapy / ara-CTP / DNA incorporation / cellular TDM / in vitro pharmacokinetic / TDM / N^4-Behenoyl-ara-C / 白血病 / 濃度曲線下面積 / 血中濃度自動シュミレーター / Pharmacokinetics / K562 / clonogenic assay / 血中濃度曲線下面積(AUC) / 時間依存性 / N^4-behenovl-ara-C
Research Abstract

1. Pharmacokinetic study of ara-CTP, an intracellular active metabolite of ara-C.
ara-CTP was measured in leukemic cells by the newly established sensitive method in 25 leukemic patients receiving ara-C or log-acting ara-C, BHAC at low or conventional doses. The ara-CTP concentrations differed by the administration methods, doses, and patients, and were not predicted from the plasma ara-C concentrations. As the maintenance of the plasma ara-C was important for the retention of ara-CTP in the cell, continuous infusion of ara-C and BHAC produced ara-CTP efficiently. In BHAC therapy, patients with complete remission achieved greater ara-CTP amounts than those without remission, suggesting that ara-CTP would 6e a crucial parameter for the therapeutic efficacy of BHAC. Myelosuppression was correlated to the plasma ara-C level, suggesting that normal hematopoietic stem cells have similar sensitivity to ara-C among individuals.
2. Detection of ara-C incorporated into DNA.
The detection method fo … More r ara-C incorporated into DNA was established. DNA was separated from acid insoluble fraction of leukemic cells after treatment with ara-C. The DNA was digested enzymatically to nucleosides that included ara-C. ara-C was isolated by high performance liquid chromatography, followed by liophilization. The recovery of each step was over 90 %. Radioimmunoassay will be applied to the isolated sample using anti-ara-C serum to confirm its ara-C concentration.
3. Cytotpxic effects evaluated by a new computer-controlled in vitro pharmacokinetic simulation system.
Cytotoxicity was compared between a pharmacokinetically simulated condition and a conventional culture system condition. The survival rates of the cell line K562 incubated with the simulated ara-C infusions for 2, 4, 8, and 16 h demonstrated that the cytotoxicity of ara-C was time-dependent. In contrast, under a conventional culture system, no time-dependent inhibition was observed. Similarly, the simulations of the infusion of daunorubicin for 0.5, 2, 4, and 8 h revealed that the cytotoxic effect of daunorubicin was concentration-dependent Less

Report

(5 results)
  • 2001 Annual Research Report   Final Research Report Summary
  • 2000 Annual Research Report
  • 1999 Annual Research Report
  • 1998 Annual Research Report
  • Research Products

    (41 results)

All Other

All Publications (41 results)

  • [Publications] Takanori Ueda: "Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : The ALL90 study of the Japan Adult Leukemia Study Group"Int. J. Hematol.. 68. 279-289 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Shinji Kishi: "Evaluation of cell-killing effects of 1-β-D-Arabinofuranosyloytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system"Cancer Res.. 59. 2629-2637 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Haruyuki Takemura: "Simultaneous treatment with 1-β-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells"Cancer Res.. 61. 172-177 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takahiro Yamauchi: "Monitoring of intracellular 1-β-D-arabinofuranosyloytosine 5'-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low-and conventional-doses"Jpn. J. Cancer Res.. 92. 546-553 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takahiro Yamauchi: "Close correlation of 1-β-D-arabinofuranosylcytosinc 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N^4-behenoyl-1-β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia"Jpn. J. Cancer Res.. 92. 975-982 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Toshihiro Fukushima: "A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma : relationship with leukocytopenia and neutropenia"Int. J. Hematol.. 74. 297-302 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] 上田孝典: "白血病とAra-C大量療法"大野竜三編、医薬ジャーナル社. 8 (2001)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takaisi Ueda: "Resjiffise-oriented individualized induction therapy with six drags followed bv four courses of intensive consolidation, 1 year maintenance and intensification therapy: The ALL90 study of the Japan Adult Leukemia Study Group."

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Shinji Kishi: "Evaluationf of cell-killing effects of 1-β-D-Arabinofuranosylcytosine and daunorubicin bv a new computer-controlled in vitro pharmacokinetic simulation system."Cancer Res. 59. 2629-2637 (1999)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Haruvuki Takemura: "Simultaneous treatment with 1-β-D-arabinofuranosvlcvtosine and rfannnnihirin nuniras I cross-resistance to both drugs due to a combinationspecific mechanism in HL60 cells."Cancer Res.

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takahiro Yamauchi: "Monitoring of intracellular 1-β-D-arabinofuranosylcytosine 5'-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low- and conventional- doses."Jpn. J. Cancer Res. 92. 546-553 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Takahiro Yamauchi: "Close correlation of 1-β-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N^4-behenoyl-1-β-Darabinofuranosylcytosine therapy for acute myelogenous leukemia."Jpn. J. Cancer Res. 92. 975-982 (2001)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Toshihiro Fukushima: "A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia."fInt. J. Hematol.

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2001 Final Research Report Summary
  • [Publications] Haruyuki Takemura: "Simultaneous Treatment with 1-β-D-Arabinofuranosylcytosine and Daunorubicin Induces Cross-Resistance to Both Drugs due to a Combination-specific Mechanism in HL60 Cells"Cancer Res.. 61. 172-177 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Takahiro Yamauchi: "Monitoring of intracellular 1-β-D-Arabinofuranosylcytosine 5'-triphosphate in 1-β-D-arabinofuranosylcytosine therapy at low- and conventional- doses"Jpn. J. Cancer Res.. 92. 546-553 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Takahiro Yamauchi: "Close correlation of 1-β-D-Arabinofuranosylcytosine 5'-triphosphate, an intercellular active metabolite, to the therapeutic efficacy of N^4-behenoyl-1-β-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia"Jpn. J. Cancer Res.. 92. 975 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Toshihiro Fukushima: "A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma : relationship with leukocytopenia and neutropenia"Int. J. Hematol.. 74. 297-302 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Adel Badran Abdul Kader: "Time sequential expression of markers of apoptosis induced by 1-β-D-Arabinofuranosylcytosine in human T-lymphoblastic leukemia CCRF-CEM cells"Anticancer Res.. 21. 1987-1995 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 山内高弘: "Ara-C における Cellular TDM の臨床応用"臨床医薬. 17. 1129-1134 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] 上田孝典: "白血病と Ara-C 大量療法"大野竜三編、南江堂. 8 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kunihiro Inai: "Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil."Leukemia Res.. 24. 761-768 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Toshihiro Fukushima: "Effect of PSC 833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug-resistant K562 cells."Leukemia Res.. 24. 249-254 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Shinji Kishi: "Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia."Int J Hematol.. 1. 172-179 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Haruyuki Takemura: "Cross-resistance to ara-C and daunorubicin Induced by slimultaneous treatment with both drugs showed a combination-spesific mechanism in HL60/AD Ccells."AACR 91st Annual Meeting Proceedings.. 762-762 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Hiroshi Tsutani: "Latent overproductive heyperuricemia increases in patients during the intermittent phase of gouty arthritis under long-term antihyperuricemic treatment"Mod Rheumatol. 10. 207-210 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 高木和貴: "慢性骨髄性白血病においてhydroxyureaの長期投与中に認めた発汗障害."臨床血液. 41. 1214-1219 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Yasukazu Kawai: "Leukemia 2000 towards the Cure, Program and Abstract Book."Pronounced induction of apoptosis by aphidicolin in cytarabine-treated human leukemic cells.. 79 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Shinji Kishi: "Evalution of cell-killing effects of 1-β-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system."Cancer Res.. 59・11. 2629-2637 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Toshihiro Fukushima: "Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells."Leukemia Res.. 23・1. 37-42 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Takashi Nakayama: "A novel Philadelphia chromosome-positive cell line with multipotential properties."Anticancer Res.. 69・4. 256-259 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Takahiro Yamauchi: "Successful salvage treatment with irinotecan (CPT-11) of recurrent malignant lymphoma in an aged patient; and CPT-11 pharmacokinetics."Int. J. Hematol.. 69・3. 165-169 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Hiroshi Tsutani: "Hepatic tumor rupture following effectual treatment with irinotecan in a patient with highly refractory malignant lymphoma."Int. J. Hematol.. 70・3. 178-180 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Toshihiro Fukushima: "Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line."Anticancer Res.. 19. 5111-5116 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Toshihiro Fukushima: "Effect of PSC833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells" Leukemia Res.23. 37-42 (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Toshihiro Fukushima: "Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin" Leukemia Res.22. 625-629 (1999)

    • Related Report
      1998 Annual Research Report
  • [Publications] Takanori Ueda: "Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy : the ALL90 study of the Japan Adult Leukemia Study Group" Int.J.Hematol.68・3. 279-289 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] M.Tanimoto: "Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia : The ALL-87 study of the Japan Adult Leukemia Study Group(JALSG)" Int.J.Hematol.68・4. 421-429 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 上田孝典: "ara-C, その誘導体の臨床応用におけるPharmacokineetics及びPharmacodynamicsの意義" プリン・ピリミジン代謝. 22・2. 200-203 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 上田孝典: "Cytosine arabinoside(ara-C)の作用機序, その概念の変遷" プリン・ピリミジン代謝. 22・1. 1-9 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Takanori Ueda: "Purine and Pyrimidine Metabolism in Man IX" Plenum Publishing Corporation, 866 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] 上田孝典 編著: "医薬ジャーナル社" 造血器腫瘍における薬剤の使い方-合理的投与法と展望-, 349 (1998)

    • Related Report
      1998 Annual Research Report

URL: 

Published: 1999-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi